STTR Phase I: Proof of Concept of a Digital Magnetic Biosensor

STTR 第一阶段：数字磁性生物传感器的概念验证

• 批准号: 0319868
• 负责人: Malcolm Gregory
• 金额: $ 10万
• 依托单位: Digimmune Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2004-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0319868&HistoricalAwards=false
• 关键词: STTR; Phase; Proof; Concept; Digital

This Small Business Technology Transfer (STTR) Phase I project seeks to develop the detector portion of a novel Digital Magnetic Biosensor ("DIBS"). The primary goal is to establish the feasibility of detecting and counting individual protein molecules using magnetic reagents and digital detector technology adapted from existing magnetic data-storage devices. A prototype microfluidic device will be built and used to investigate detection limits. Products are envisioned that use multiple DIBS in a wide range of disposable diagnostic "cards" that are driven by a hand-held analyzer based on a popular PDA platform. The device will be capable of single molecule detection/resolution, simultaneous analysis of multiple analytes in a single pinprick-sized sample, giving results within minutes. An initial conservative target of 1000 molecules per sample is a first objective. The commercial application of this product will primarily be in diagnostic medicine. Applications in remote environmental testing and homeland defenses monitoring are also possible. The initial targeted customers for these products are distributed healthcare providers who wish to provide rapid and cost-effective quantitative immunoassay-based diagnostic tests on site. These include primary healthcare physician practices, specialist healthcare centers, and hospital emergency rooms. A large potential secondary market for home testing is also anticipated.

该小企业技术转让（STTR）第一阶段项目旨在开发新型数字磁生物传感器（“DIBS”）的检测器部分。 主要目标是建立使用磁性试剂和数字检测器技术检测和计数单个蛋白质分子的可行性，该技术适用于现有的磁性数据存储设备。 将建立一个原型微流体装置，并用于研究检测限。 设想在广泛的一次性诊断“卡”中使用多个DIBS的产品，所述一次性诊断“卡”由基于流行的PDA平台的手持式分析仪驱动。 该设备将能够进行单分子检测/解析，同时分析单个针尖大小的样品中的多种分析物，并在几分钟内给出结果。 每个样品1000个分子的初始保守目标是第一目标。 该产品的商业应用将主要用于诊断医学。 在远程环境测试和国土防御监测中的应用也是可能的。 这些产品的最初目标客户是希望在现场提供快速且具有成本效益的定量免疫分析诊断测试的分布式医疗保健提供商。 这些包括初级保健医生的做法，专科医疗保健中心和医院急诊室。 预计还将有一个巨大的潜在的家庭测试二级市场。